Hepatitis Monthly

Official Journal of Research Center for Gastroenterology and Liver Diseases

Journal Information Boards and committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Reviewer and AE Registration Form Support Contact Us

APC

Authors Guide Submit Manuscript

Crossref

1. Performance of a rapid diagnostic test for screening of hepatitis C in a real-life prison setting

- Heidar Sharafi

- Hossein Poustchi

- Fatemeh Azimian

- Babak Tamadoni

- Rashid Ramezani

- Mohamad Mehdi Gouya

- Mahdi Sheikh

- Farnaz Hashemi

- Mehrzad Tashakorian

- Ramin Alasvand

- Seyed Moayed Alavian

- Shahin Merat

2. Sofosbuvir and Ribavirin with or Without Pegylated-Interferon in Hepatitis C Virus Genotype-2 or -3 Infections: A Systematic Review and Meta-Analysis

- Mohammad Ehsan Bayatpoor

- Mohammad Hossein Khosravi

- Heidar Sharafi

- Mohammad Saeid Rezaee-Zavareh

- Bita Behnava

- Seyed Moayed Alavian

3. Signature of natural resistance in NS3 protease revealed by deep sequencing of HCV strains circulating in Iran

- Lize Cuypers

- Marijn Thijssen

- Arash Shakibzadeh

- Ward Deboutte

- Jamal Sarvari

- Farzaneh Sabahi

- Mehrdad Ravanshad

- Mahmoud Reza Pourkarim

4. Efficacy and Safety of Generic Sofosbuvir/Ledipasvir Fixed-Dose Combination in Iranian Patients with Chronic Hepatitis C Virus Infection

- Heidar Sharafi

- Mehri Nikbin

- Seyed Hoda Alavian

- Bita Behnava

- Seyed Moayed Alavian

5. Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis

- Mohammad Saeid Rezaee-Zavareh

- Khashayar Hesamizadeh

- Bita Behnava

- Seyed Moayed Alavian

- Mohammad Gholami-Fesharaki

- Heidar Sharafi

6. Molecular Tracing of Hepatitis C Virus Genotype 1 Isolates in Iran: A NS5B Phylogenetic Analysis with Systematic Review

- Khashayar Hesamizadeh

- Seyed Moayed Alavian

- Azar Najafi Tireh Shabankareh

- Heidar Sharafi

7. Methadone Maintenance Therapy (MMT) Clients Should Be More Noticed for Hepatitis C Elimination in Iran

- Hamidreza Karimi-Sari

- Seyed Moayed Alavian

8. Aflatoxin B1 exposure and the risk of hepatocellular carcinoma in Iranian carriers of viral hepatitis B and C

- Nasim Habibi

- Mohsen Nassiri-Toosi

- Heidar Sharafi

- Seyed Moayed Alavian

- Masoomeh Shams-Ghahfarokhi

- Mehdi Razzaghi-Abyaneh

9. Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C

- Hala Rady Ahmed

- Nancy G. F. M. Waly

- Rehab Mahmoud Abd El-Baky

- Ramadan Yahia

- Helal F. Hetta

- Amr M. Elsayed

- Reham Ali Ibrahem

- Philippe Gallay

10. Identification of NS5B resistance-associated mutations in hepatitis C virus circulating in treatment-naïve Cameroonian patients

- Aristide Mounchili-Njifon

- Abdou Fatawou Modiyinji

- Pretty Rosereine Mbouyap

- Chavely Gwladys Monamele

- Moise Henri Moumbeket-Yifomnjou

- Philipe Herman Njitoyap Mfombouot

- Gisele Liliane Machuetum

- Pascal Ibrahim Toueyem

- Simon Frederic Lissock

- Paul Alain Tagnouokam-Ngoupo

- Jean Paul Assam Assam

- Richard Njouom

11. Negative Correlation of Interleukin-38 Serum Level with Alkaline Phosphatase and Persistent Hepatitis C Infection

- Najmeh Rokhtabnak

- Mohammad Reza Ataollahi

- Morvarid Asadipour

- Mohammad Ali-Hassanzadeh

- Pooria Fazeli

- Soolmaz Khansalar

- Esmaeel Ghani

- Kurosh Kalantar

12. Lurking epidemic of hepatitis C virus infection in Iran: A call to action

- Reza Taherkhani

- Fatemeh Farshadpour

13. Hepatitis C virus infection in Iran: A review of current prevalence and preventive strategies from a developing country

- Marcarious M. Tantuoyir

- Muhammed Camara

- Marjan Sohrabi

- SeyedAhmad SeyedAlinaghi

- Zahra Ahmadinejad

14. Evaluating Drug Resistant Mutations to HCV NS3 Protease Inhibitors in Iranian Naïve Patients

- Tayebeh Hashempour

- Behzad Dehghani

- Zahra Mousavi

- Maryam Yahaghi

- Zahra Hasanshahi

- Javad Moayedi

- Tahereh Akbari

- Mohammad Ali Davarpanah

15. Assessing the Quality of Clinical Practice Guidelines in the Middle East and North Africa (MENA) Region: A Systematic Review

- Saja H Almazrou

- Layan A Alsubki

- Norah A Alsaigh

- Wadha H Aldhubaib

- Sharifah M Ghazwani

16. First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients

- Zahra Hasanshahi

- Ava Hashempour

- Farzane Ghasabi

- Javad Moayedi

- Zahra Musavi

- Behzad Dehghani

- Heidar Sharafi

- Hassan Joulaei

17. Hepatitis B and Hepatitis C in Patients with Inherited Disorders of Hemoglobin in Sistan and Baluchistan Province, Iran

- Soheila Khosravi

- Heidar Sharafi

- Esmaeil Sanei Moghadam

- Fariba Heidari

- Mahmod Naibzadeh

- Seyed Moayed Alavian

18. Assessment of Hepatitis C Virus RNA in Peripheral Blood Mononuclear Cells as a Predictor of Response to Pegylated-Interferon and Ribavirin: A Cohort Study

- Seyyed Mohammad Miri

- Heidar Sharafi

- Shima Salimi

- Farah Bokharaei-Salim

- Bita Behnava

- Maryam Keshvari

- Pegah Karimi Elizee

- Hosein Keyvani

- Seyed Moayed Alavian

19. The Efficacy and Safety of Sofosbuvir/Daclatasvir Fixed-Dose Combination in Iranian Hemodialysis Patients with Hepatitis C Virus Infection

- Kasra Ghanaat

- Heidar Sharafi

- Seyed Moayed Alavian

20. Treatment of HCV Infection with Direct-Acting Antiviral Agents in Patients with HIV/HCV Co-Infection: A Systematic Review

- Saman Mohazzab-Torabi

- Fardin Dolatimehr

- Heidar Sharafi

- Mahdi Safi-Abadi

- Mohammad Saeid Rezaee-Zavareh

- Ehsan Bayatpour

- Hamidreza Karimi-Sari

- Seyed Moayed Alavian

21. Awareness Campaign in (bio)Medical Students in Iran: a model for increasing the knowledge regarding hepatitis B and C

- H. Karimi-Sari

- M.E. Bayatpoor

- S.M. Alavian

22. An on-site community-based model for hepatitis C screening, diagnosis, and treatment among people who inject drugs in Kerman, Iran: The Rostam study

- Ali Mirzazadeh

- Samira Hosseini-Hooshyar

- Armita Shahesmaeili

- Heidar Sharafi

- Mohammad Shafiei

- Jasem Zarei

- Ghazal Mousavian

- Fatemeh Tavakoli

- Nima Ghalekhani

- Mostafa Shokoohi

- Mehrdad Khezri

- Soheil Mehmandoost

- Mohammad Reza Shojaei

- Mohammad Karamouzian

- Alya Briceno

- Meghan D. Morris

- Seyed Moayed Alavian

- Ali-Akbar Haghdoost

- Hamid Sharifi

- Kimberly A. Page

23. The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3

- Shahin Merat

- Amir Houshang Sharifi

- Arghavan Haj-Sheykholeslami

- Hossein Poustchi

- Babak Fattahi

- Alireza Nateghi-Baygi

- Seyed Moayed Alavian

- Reza Malekzadeh

24. Pooled Prevalence of NS5A Resistance-Associated Substitutions in Chronic HCV Genotype 3 Infection: A Study Based on Deposited Sequences in GenBank

- Heidar Sharafi

- Saman Ghalamkari

- Alireza Hassanshahi

- Seyed Moayed Alavian

25. Treatment of Hepatitis C Infection with Direct-Acting Antiviral Agents in Liver-Transplant Patients: A Systematic Review and Meta-Analysis

- Mohammad Saeid Rezaee-Zavareh

- Khashayar Hesamizadeh

- Heidar Sharafi

- Seyed Moayed Alavian

26. The prevalence of hepatitis C virus infection in thalassemia patients in Iran from 2000 to 2017: a systematic review and meta-analysis

- Masoud Behzadifar

- Hassan Abolghasem Gorji

- Nicola Luigi Bragazzi

27. Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem?

- Heidar Sharafi

- Seyed Moayed Alavian

28. Update on the Prevalence of Hepatitis C Virus Infection Among Iranian General Population: A Systematic Review and Meta-Analysis

- Babak Mirminachi

- Zahra Mohammadi

- Shahin Merat

- Afarin Neishabouri

- Amir Houshang Sharifi

- Seyed Hoda Alavian

- Hosein Poustchi

- Reza Malekzadeh

29. Controversies in the Screening of Hepatitis C Virus Among First-Degree Family Members of the Affected Patients

- Parivash Davoodian

- Hamidreza Mahboobi

30. Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders

- Heidar Sharafi

- Bita Behnava

- Alireza Azizi-saraji

- Ali Namvar

- Ali Anvar

- Shima Salimi

- Seyed Moayed Alavian

31. Update on Recommendations for the Clinical Management of Hepatitis C in Iran 2017

- Seyed Moayed Alavian

- Heidar Sharafi

32. Prevalence of Occult HCV Infection in Hemodialysis and Kidney-Transplanted Patients: A Systematic Review

- Fardin Dolatimehr

- Mohammad Hossein Khosravi

- Mohammad Saeid Rezaee-Zavareh

- Seyed Moayed Alavian

33. The Role of Polymorphisms Near IFNL3 Gene as Predictors of Residual HCV RNA in Buffy Coat after Successful Antiviral Therapy

- Seyyed Mohammad Miri

- Heidar Sharafi

- Ali Pouryasin

- Bita Behnava

- Maryam Keshvari

- Shima Salimi

- Pegah Karimi Elizee

- Seyed Moayed Alavian

34. Prevalence of Naturally Occurring Resistance Associated Substitutions in NS3/4AProtease Inhibitors in Iranian HCV/HIV Infected Patients

- Kazem Baesi

- Ali Akbar Velayati

- Masoumeh Farrokh Ashtiani

- Kamal Fakhredini

- Mohammad Banifazl

- Mona Sadat Larijani

- Parya Basimi

- Amitis Ramezani

35. Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis

- Fardin Dolatimehr

- Hamidreza Karimi-Sari

- Mohammad Saeid Rezaee-Zavareh

- Seyed Moayed Alavian

- Bita Behnava

- Mohammad Gholami-Fesharaki

- Heidar Sharafi

36. Hepatitis Awareness Bus: A Model for Finding Unknown Hepatitis B and C Infections

- Masood Ziaee

- Morteza Hajihosseini

37. Letter: the efficacy of interferon‐free regimens in HCV‐related Child C cirrhosis needs careful interpretation

- M. S. Rezaee‐Zavareh

- S. M. Alavian

38. Research progress on the direct antiviral drugs for hepatitis C virus

- Jianjun Gao

- Chuanxia Ju

39. Global elimination of hepatitis C virus infection: Progresses and the remaining challenges

- Reza Taherkhani

- Fatemeh Farshadpour

40. Eradication of hepatitis C virus infection in thalassemia patients in Iran using various treatment strategies

- Meisam Moghimbeygi

- Seyed Moayed Alavian

41. Seroprevalence of Hepatitis C Virus among Blood Donors in Middle Eastern Countries: A Systematic Review and Meta-Analysis

- Hossein Ghaderi-Zefrehi

- Heidar Sharafi

- Farzin Sadeghi

- Mohammad Gholami-Fesharaki

- Alireza Farasat

- Fatemeh Jahanpeyma

- Seyed Moayed Alavian

42. Acute changes in cardiac function by direct acting antiviral therapy for hepatitis C−infected patients with thalassemia

- Arezoo Khosravi

- Hamidreza Karimi‐Sari

- Mahdi Abedi‐Andani

- Bita Behnava

- Ali Namvar

- Ali Anvar

- Seyed Moayed Alavian

43. Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in iranian population

- Amitis Ramezani

- Kazem Baesi

- Mohammad Banifazl

- Minoo Mohraz

- Farzin Khorvash

- Majid Yaran

- Payam Tabarsi

- Amir hosein Dalirrooyfard

- Fatemeh Motevalli

- Anahita Bavand

- Arezoo Aghakhani

44. Chronic Hemodialysis Patients; Special Group for Hepatitis C Elimination Programs in Iran

- Hamidreza Karimi-Sari

- Seyed Moayed Alavian

45. Update on Transmission Modes of Hepatitis C Virus Among Volunteer Iranian Blood Donors: Analysis of a Matched Case-Control Study by Penalized Conditional Logistic Regression

- Fahimeh Ranjbar Kermani

- Kamran Mousavi Hosseini

- Sedigheh Amini Kafi-abad

- Mahtab Maghsudlu

- Zohreh Sharifi

- Mohammad Ali Mansournia

- Seyed Moayed Alavian

46. SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial

- Shahin Merat

- Amir-Houshang Sharifi

- Hossein Poustchi

- Eskandar Hajiani

- Abdolsamad Gharavi

- Jalal Karimi

- Fariborz Mansour-Ghanaei

- Mohammad-Reza Fattahi

- Lida Ahmadi

- Mohammad-Hossein Somi

- Hamid Kalantari

- Mohammad-Reza Ghadir

- Farshad Sheikhesmaeili

- Nadieh Baniasadi

- Masoudreza Sohrabi

- Seyedhamid Moosavy

- Masood Ziaee

- Mohammad-Javad Zahedi

- Marjan Mokhtare

- Shahnaz Sali

- Babak Sayad

- Behrooz Afshar

- Alireza Bakhshipour

- Abazar Parsi

- Afsaneh Sharifian

- Taghi Amiriani

- Zeinab Malekzadeh

- Dorsa Merat

- Azita Ganji

- Fereidoun Rahmani-Samani

- Raika Jamali

- Masoomeh Sofian

- Mohammad Ghezlou

- Amir Ali Sohrabpour

- Ladan Goshayeshi

- Seyed-Mohammad Valizadeh-Toosi

- Layli Eslami

- Iradj Maleki

- Ahmad Hormati

- Ali-Akbar Shayesteh

- Elahe Shayesteh

- Alireza Norouzi

- Zahra Abna

- Alireza Janbakhsh

- Hafez Fakheri

- Mohammad Minakari

- Hossein Sardarian

- Adel Fallah Ghajary

- Mojtaba Fattahi-Abdizadeh

- Maryam Latifnia

- Fatemeh Roozbeh

- Shahram Agah

- Saba Fakhrieh-Asl

- Alireza Nateghi-Baygi

- Babak Fattahi

- Helia Nateghi-Baygi

- Andrew Hill

- Reza Malekzadeh

47. Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation

- Ashly E. Jordan

- David C. Perlman

- Charles M. Cleland

- Katarzyna Wyka

- Bruce R. Schackman

- Denis Nash

48. Patient-reported outcomes of sleep, mood and quality of life after treatment of chronic hepatitis C infection using direct-acting antiviral agents

- H. Karimi-Sari

- M.A. Hosseini

- N. Nikjoo

- M.S. Bagheri Baghdasht

- S.M. Alavian

49. Comment on ‘Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study’

- Seyed M. Alavian

- Heidar Sharafi